Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “combination”

418 pharma patents match "combination" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 418
Index total 30,257
Page 10 / 18

Quick answer

This filtered view shows 418 pharmaceutical patents matching "combination" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

418 results for “combination” · 30,257 patents in full index Clear search

  1. US 10576096

    Tumor-selective combination therapy

    The Board of Regents of the University of Texas System · Granted Mar 3, 2020 · Expires Feb 27, 2040

    granted
  2. US 10568873

    Safranal-sorafenib combination therapy for liver cancer

    UNITED ARAB EMIRATES UNIVERSITY · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted
  3. US 2020040086

    PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY

    BERLIN CHEMIE AG [DE] · Granted Feb 6, 2020 · Expires Feb 1, 2040

    granted
  4. US 10544223

    Combination therapy with an anti-axl antibody-drug conjugate

    ADC THERAPEUTICS SA · Granted Jan 28, 2020 · Expires Jan 23, 2040

    granted
  5. US 10532096

    Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  6. US 10532056

    Therapeutic compositions, combinations, and methods of use

    VERASTEM, INC. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  7. US 10526414

    Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases

    VACCINEX, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  8. US 10517860

    Combination of pimavanserin and cytochrome P450 modulators

    ACADIA Pharmaceuticals Inc. · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted
  9. US 10500277

    Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma

    EnGeneIC Molecular Delivery Pty Ltd · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted
  10. US 10493030

    Combination HIV therapeutic

    Aphios Corporation · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted
  11. US 10485796

    LPT-723 and immune checkpoint inhibitor combinations and methods of treatment

    Biomed Valley Discoveries, Inc. · Granted Nov 26, 2019 · Expires Nov 21, 2039

    granted
  12. US 10478430

    Compounds useful as inhibitors of ATR kinase and combination therapies thereof

    Vertex Pharmaceuticals Incorporated · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted
  13. US 10471144

    Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer

    Provectus Pharmatech, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  14. US 10471142

    Combination therapy using immunoglobulin and C1-Inhibitor

    THE GOVERNMENT OF THE UNITED STATES OF AMERICA · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted
  15. US 10463654

    Combination therapies for treating cancer

    RedHill Biopharma Ltd. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  16. US 10463652

    Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof

    VTV THERAPEUTICS LLC · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted
  17. US 10456390

    Combinations comprising MABA compounds and corticosteroids

    Almirall, S.A. · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted
  18. US 10451610

    Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PARP1

    The Board of Regents of the University of Texas System · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted
  19. US 10434174

    Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  20. US 10434078

    GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes

    The Regents of the University of California · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted
  21. US 10426786

    Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids

    The Regents of the University of California · Granted Oct 1, 2019 · Expires Sep 26, 2039

    granted
  22. US 10420812

    Drug combinations and uses in treating a coughing condition

    Infirst Healthcare Limited · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  23. US 10406125

    Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the H2O2 level in cancer cells of a subject

    ADVANCED BIODESIGN · Granted Sep 10, 2019 · Expires Sep 5, 2039

    granted
  24. US 10376588

    Etanercept formulations stabilized with combinations of sugars and polyols

    Coherus BioSciences, Inc. · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted